Financial Performance - Operating revenue for the first nine months was ¥128,616,509.50, a growth of 34.55% compared to the same period last year[18]. - Net profit attributable to shareholders was ¥20,830,130.97, reflecting a 38.41% increase year-over-year[18]. - The net profit excluding non-recurring gains and losses was ¥16,850,310.60, a significant increase of 642.54% compared to the previous year[20]. - Basic earnings per share rose to ¥0.0508, up 21.53% from ¥0.0418 in the same period last year[20]. - The weighted average return on net assets improved to 3.50%, an increase of 0.21 percentage points year-over-year[20]. - Total revenue for Q3 2019 reached ¥46,698,960.37, a 103.5% increase from ¥22,954,539.91 in Q3 2018[55]. - Net profit for Q3 2019 was ¥3,320,072.85, compared to a net loss of ¥2,877,979.46 in Q3 2018[58]. - The company reported a gross profit of ¥2,507,840.63 for Q3 2019, compared to a gross loss of ¥10,742,607.23 in Q3 2018[58]. - Total operating revenue for Q3 2019 was approximately ¥46.70 million, a 104.0% increase from ¥22.92 million in Q3 2018[64]. - Net profit for Q3 2019 reached approximately ¥3.72 million, compared to a net loss of ¥2.19 million in Q3 2018[67]. Assets and Liabilities - Total assets increased to ¥1,670,026,499.56, up 133.13% from the previous year[18]. - Net assets attributable to shareholders reached ¥1,447,734,984.69, representing a 203.57% increase year-over-year[18]. - Total current assets amounted to ¥1,108,136,574.13, a significant increase from ¥233,469,859.12 in the previous year, representing a growth of approximately 373%[39]. - Total non-current assets increased to ¥561,889,925.43 from ¥482,869,183.34, marking a growth of around 16%[43]. - Total liabilities decreased to ¥222,291,514.87 from ¥239,441,334.74, indicating a reduction of about 7%[45]. - The company's equity attributable to shareholders rose significantly to ¥1,447,734,984.69 from ¥476,897,707.72, representing an increase of approximately 203%[45]. - Total liabilities reached ¥111,284,832.27, compared to ¥66,637,780.15 in the previous year[54]. Cash Flow - The company reported a net cash flow from operating activities of -¥38,647,780.16, a decrease of 37,145.70% compared to the previous year[18]. - Operating cash inflow for the first three quarters of 2019 was CNY 124,624,720.87, slightly up from CNY 123,035,673.82 in the same period of 2018, reflecting a growth of 1.3%[69]. - Net cash outflow from operating activities was CNY -38,647,780.16, compared to CNY -103,764.41 in the previous year, indicating a significant improvement[69]. - Cash inflow from investment activities totaled CNY 138,026,566.60, down from CNY 348,629,267.46 in the same period last year, a decrease of approximately 60.4%[73]. - Cash inflow from financing activities reached CNY 994,151,952.94, a significant increase compared to CNY 95,000,000.00 in the same period last year[75]. - The ending cash and cash equivalents balance was CNY 249,435,197.42, up from CNY 108,712,364.81 at the end of the same period last year, reflecting a growth of 129.1%[75]. Shareholder Information - The total number of shareholders reached 19,506 by the end of the reporting period[25]. - The top shareholder, BGI Group, holds 10.47% of the shares, totaling 42,919,572 shares[25]. Research and Development - R&D expenses for Q3 2019 amounted to ¥17,852,442.46, a 58.5% increase from ¥11,283,052.00 in Q3 2018[55]. - Research and development expenses for Q3 2019 were approximately ¥19.06 million, up 48.1% from ¥12.87 million in Q3 2018[64]. - The company completed a capital increase of CNY 28 million for its wholly-owned subsidiary Chengdu Microchip Pharmaceutical Co., Ltd. to support innovation drug production and R&D projects[34].